Crown Bioscience launches MuScreen™ platform for evaluating in vivo efficacy of immuno-oncology agents

April 26, 2016 – SANTA CLARA.  Crown Bioscience, a wholly owned subsidiary of Crown Bioscience International and a global drug discovery and development solutions company providing translational platforms to advance oncology and metabolic disease research, has announced the launch of MuScreen™, a new immuno-oncology (IO) service platform utilizing CrownBio’s unique fully characterized syngeneic models.

MuScreen™ will be offered as a streamlined service for in vivo pharmacodynamic (PD) and efficacy testing using up to 20 syngeneic models. Tissue microarrays can be run in parallel to the in vivo study for high throughput molecular analysis of multiple syngeneic treatment naïve tumor samples. MuScreen™ enables users to quickly identify the correct model and relevant PD effect for immuno-oncology agents. It is particularly relevant for testing combination strategies, allowing next stage decisions to be made rapidly and efficiently.

“As a leading oncology preclinical solutions provider, our ultimate goal is to deliver superior data in a well-organized and cost-effective manner,” said Qian Shi, vice president of cancer pharmacology and in vitro cancer biology at CrownBio. “By pooling our agents together in a single run, we can dramatically reduce model usage and resource requirements, thus accelerating the process while optimizing its productivity.”

By running MuScreen™ on a large scale, CrownBio is confident that the quality of PD data will improve, providing an even more complete dataset for both pharmacodynamics and efficacy studies.

Joining CrownBio’s broad range of models, including the world’s largest commercial portfolio of PDX models, the launch of MuScreen™ is testament to CrownBio’s continued commitment to providing industry-leading service for global drug discovery.

The platform will become operative the first week of May. Compounds will be enrolled into the screen on a first come, first served basis until 10 group studies have been reached. Additional orders will be given priority for enrollment into the following screening round.

For more information about MuScreen™ and CrownBio’s commitment to improving clinical outcomes, visit www.crownbio.com.

SOURCE Crown Bioscience Inc.